|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients
This item is licensed under:Creative Commons Attribution-NonCommercial 4.0 International
| Title: | Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients |
| Authors: | Imafuku, Keisuke Browse this author | | Yoshino, Koji Browse this author | | Yamaguchi, Kei Browse this author | | Tsuboi, Satoshi Browse this author | | Ohara, Kuniaki Browse this author | | Hata, Hiroo Browse this author →KAKEN DB |
| Keywords: | Malignant melanoma | | Vemurafenib | | Brain metastasis | | Drug resistance | | BRAF mutation | | Heterogeneous lesion | | LDH |
| Issue Date: | 24-Apr-2017 |
| Publisher: | Karger |
| Journal Title: | Case reports in oncology |
| Volume: | 10 |
| Issue: | 1 |
| Start Page: | 290 |
| End Page: | 295 |
| Publisher DOI: | 10.1159/000461576 |
| Abstract: | Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be also effective against brain metastasis. We encountered 3 cases with brain metastasis on vemurafenib therapy. In these cases, vemurafenib was clinically effective against metastatic lesions other than those in the brain. The brain lesions developed after the metastatic lesion had occurred. Therefore, we assume that the melanomas of the patients acquired resistance against vemurafenib. The brain metastases were treated with the cyberknife. Patients 1 and 2 without LDH elevation are still alive, but patient 3 with abnormal LDH elevation died despite the treatment. We need to carefully follow patients on vemurafenib therapy because brain metastasis can suddenly occur even if the metastatic lesion has decreased clinically. The therapeutic effect of vemurafenib against brain metastasis is poor in cases with LDH elevation. |
| Rights: | The final, published version of this article is available at http://www.karger.com/?doi=10.1159/000461576 | | https://creativecommons.org/licenses/by-nc/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/67551 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 秦 洋郎
|
